Navidea to Provide Shareholder Update
June 14 2016 - 04:45PM
Business Wire
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) announces a
conference call on Wednesday, June 15, 2016 at 5:00 p.m. ET to
provide a CRG litigation and general corporate update.
Conference Call Details
Investors and the public are invited to access the live audio
webcast through the link below. Participants who would like to ask
questions during the question and answer session must participate
by telephone also. Participants are encouraged to log-in and/or
dial-in fifteen minutes before the conference call begins. The
webcast replay is expected to be available on our investor website,
http://ir.navidea.com, approximately two to four hours after the
live event.
Event: Navidea Corporate Update for Shareholders
Conference Call Date/Time: Wednesday, June 15, 2016 5:00 p.m. ET
Webcast Link:
http://edge.media-server.com/m/p/tcre5q4r
Dial-in Number – US: (855) 897-5884 Dial in Number – Int’l: (720)
634-2940 Participant Passcode: 34301957 Replay
A webcast replay will be available on the
Investor Relations section of our website at http://ir.navidea.com
for 30 days.
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a
biopharmaceutical company focused on the development and
commercialization of precision immunodiagnostic agents and
immunotherapeutics. Navidea is developing multiple
precision-targeted products and platforms including Manocept™ and
NAV4694 to help identify the sites and pathways of undetected
disease and enable better diagnostic accuracy, clinical
decision-making, targeted treatment and, ultimately, patient care.
Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s
first commercial product from the Manocept platform, was approved
by the FDA in March 2013 and in Europe in November 2014. The
development activities of the Manocept immunotherapeutic platform
will be conducted by Navidea in conjunction with its subsidiary,
Macrophage Therapeutics. Navidea’s strategy is to deliver superior
growth and shareholder return by bringing to market novel products
and advancing the Company’s pipeline through global partnering and
commercialization efforts. For more information, please visit
www.navidea.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160614006402/en/
Navidea BiopharmaceuticalsInvestors & MediaSharon Correia,
978-655-2686Senior Director, Corporate Communications
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Feb 2024 to Mar 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Mar 2023 to Mar 2024